Childhood retinal dystrophies are highly heterogeneous

Article

A paper in the British Journal of Ophthalmology states that childhood retinal dystrophies are highly heterogeneous.

A paper in the British Journal of Ophthalmology states that childhood retinal dystrophies are highly heterogeneous.

The prospective, population-based, cross-sectional study, compiled by Professor Jugnoo S. Rahi et al., MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health, London, UK, included 241 patients with 24 different diagnoses.

All patients were aged

There was a higher rate of hereditary retinal disorders seen in males, compared to females and in Asian children compared to white children. Additional systemic disorders were found in 14% of children and 13% had dual sensory impairment.

Annual incidence of retinal disorders was 1.4/100,000 children aged between 0 and 15 years, and 22.3/100,000 children by the age of 16 years.

The study provides useful information on disease incidence, distributions and management. The results are significant to the development of future treatments and novel therapies.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.